{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-118952","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-10-27T10:06:18+00:00","discovered_at":"2026-10-27T10:10:00.222884+00:00","generated_at":"2026-10-27T10:10:12.122451+00:00","sec_items":["2.02","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aclaris ATI-052 Phase 1b hits: 45% placebo-adjusted EASI in AD, 59% FeNO cut in asthma","bullets":["AD: ATI-052 480 mg weekly cut EASI 58% vs 13% placebo at day 57, a 45% placebo-adjusted mean improvement; EASI-50 was 78% placebo-adjusted.","Itch: PP-NRS improved 43% placebo-adjusted at day 57 (38% active vs 5% worsening placebo); 33% achieved placebo-adjusted PP-NRS4 response.","Asthma: single 480 mg dose cut FeNO 59% (45 ppb) at day 15 vs 15% placebo; 58% reached FeNO ≤25 ppb; FEV1 improved 200 mL placebo-adjusted.","Safety: no Grade 3/4 TEAEs, no discontinuations, no conjunctivitis; injection-site reactions transient and mostly Grade 1.","Aclaris will prioritize ATI-052 in eosinophilic esophagitis, planning a Phase 2b trial in early 2027; preliminary cash was $204.6M at Sept 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-118952","json":"https://secwatch.observer/filing/0001104659-26-118952.json","markdown":"https://secwatch.observer/filing/0001104659-26-118952.md","text":"https://secwatch.observer/filing/0001104659-26-118952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/0001104659-26-118952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/acrs-20261027x8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-27T10:10:12.122451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}